March 31, 2017 Off

Kiadis Pharma reports €1.1M loss for 2016

By Dino Mustafić

Kiadis Pharma, a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, has reported its audited annual results for the year ended December 31, 2016.

March 31, 2017 Off

argenx kicks off phase II of immune thrombocytopenia treatment study

By Dino Mustafić

argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, has started dosing of the first patient in a Phase II proof-of-concept study of ARGX-113 in patients with primary immune thrombocytopenia (ITP).

March 30, 2017 Off

Oncodesign reports €0.6M profit for 2016

By Dino Mustafić

Oncodesign, a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, has reported its full-year 2016 results.